Controversy and consensus in the management of upper gastrointestinal disease in primary care

International Journal of Clinical Practice

Volumn 51, Issue 4, 1997, Pages 239-243

  Whitaker, M J ^a,d   Brun, J ^b   Carelli, F ^c  

^a Intl Castro Primary Care Group   (United Kingdom)

^b Intl Castro Primary Care Group   (Sweden)

^c Intl Castro Primary Care Group   (Italy)

^d Pentrefelin   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DYSPEPSIA; FAMILY PRACTICE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; PRACTICE GUIDELINES; PREVALENCE;

EID: 0030799704     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Jones R, Murfin D. Gastrointestinal problems in the community and in general practice. In: Jones R. Ed. Gastrointestinal Problems in General Practice. Oxford: Oxford University Press, 1993.
2. Colin-Jones DG, Bloom B, Bodemar G et al. Management of dyspepsia: report of a working party. Lancet 1988; 1: 576-579.
3. Talley NJ. Colin-Jones D, Koch KL et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroeraerol Int 1991; 4: 145-160.
4. Halter F, Miazza B, Brignoli R. Cisapride or cimetidine in the treatment of functional dyspepsia: results of a double blind, randomized, Swiss multicentre study. Scand J Gastroenterol 1994; 29: 618-623.
5. Heading RC and the Dyspepsia Study Group. Dyspeptic symptoms in general practice: a multicentre UK study. J Drug Dev Clin Pract 1995; 7: 109-117.
6. Inoue M, Sekiguchi T, Harasawa S et al. Dyspepsia and dyspepsia subgroups in Japan: symptom profiles and experience with cisapride. Scand J Gastroenterol 1994; 29: 36-39.
7. Gorodokin G, Grosman I, Holt L et al. Probing perceptions of dyspepsia. World Congr Gastroenterol 1994; 1097 (Abstract).
8. Valori RM, Brown CM, Strangeways P. Dyspepsia workshop for family doctors reduce dyspepsia drug costs: a controlled trial. DDW 1996; A-289 (Abstract).
9. Bennett JR. Dyspepsia, nausea and vomiting. In: Misiewicz JJ, Pounder RE, Venables CW, Eds. Diseases of the Gut and Pancreas, 2nd ed. London: Blackwell Scientific Publications 1994; 15-74.
10. Heading RC. Definitions of dyspepsia. Scand J Gastroenterol 1991; 26(Suppl 182): 1-6.
11. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-1268.
12. Knill-Jones RP. Diagnostic systems as an aid to clinical decision making. BMJ 1987; 295: 1392-1396.
13. Oddson E, Binder V, Thorgeirsson T et al. A prospective comparative study of clinical and histological characteristics in Icelandic and Danish patients with gastric ulcer, duodenal ulcer and X-ray negative dyspepsia. I. Design and clinical features. Scand J Gastroenterol 1977; 12: 689-694.
14. Jones RH, Lydeard SE, Hobbs FD et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-405.
15. Agréus L, Svärdsudd K, Nyrén O. Tibblin G The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. Scand J Gastroenterol 1994; 29: 102-109.
16. Lagarde SP, Spiro HM. Non-ulcer dyspepsia. Clin Gastroenterol 1984; 13: 437-446.
17. Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: comparison of consumers and non-consulters. J R Coll Gen Pract 1989; 39: 495-498.
18. Johannessen T, Petersen H, Kleveland PM et al. The predictive value of history in dyspepsia. Scand J Gastroenterol 1990; 25: 689-697.
19. Jones RH. What happens to patients with non-ulcer dyspepsia after endoscopy? Practitioner 1988; 232: 75-78.
20. Hungin APS, Thomas PR. Bramble MG et al. What happens to patients following open access gastroscopy? An outcome study from general practice. Br J Gen Pract 1994; 388: 519-521.
21. Korman MG. Quality of life in duodenal ulcer. Scand J Gastroenterol 1993; 28(Suppl 199): 28-31.
22. Camilleri M. Nonulcer dyspepsia: a look into the future. Mayo Clin Proc 1996; 71: 614-622.
23. Forbat LN, Gribble RJ, Baron JH. Gastrointestinal endoscopy in the young. BMJ 1987; 295: 365.
24. Lockhart SP, Schofield PM, Gribble RJ, Baron JH. Upper gastrointestinal endoscopy in the elderly. BMJ 1985; 290: 283.
25. Heatley RV, Rathbone BJ. Dyspepsia: a dilemma for doctors? Lancet 1987; ii: 779-782.
26. Fehr HF. Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Scand J Gastroenterol 1993; 28(Suppl 195): 40-45.
27. Holtmann G, Huber J, Gschossmann J et al. H. pylori and functional dyspepsia: increased serum antibodies an independent risk factor. Endoscopy 1995; 27(7): A960 (Abstract)
28. Patel P, Khulusi S, Mendall MA et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995; 346: 1315-1318.
29. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987; 28: 527-532.
30. Stanghellmi V, Tosetti C, Paternicò A et al. Risk indicators of delayed gastric emptying of solids in 343 patients with functional dyspepsia. Gastroenterology 1996; 110: 1036-1042.
31. Tosetti C, Stanghellini V, Paternicò A et al. Distinct functional dyspepsia subgroups characterized by different gastric emptying can be identified by an appropriate questionnaire. Neurogastroenterol Mot 1996; 8: 195 (Abstract).
32. Coutant G, Francois I, De Nutte N et al. Dose-response study of cisapride in the management of 'non-ulcer dyspepsia'. Prog Med 1987; 43(Suppl 1): 91-96.
33. Hammer B, Staub P, Meyer P and the Omega Project Group. Triage, probatory therapy with cisapride and follow-up in functional reflux and dyspepsia. Gut 1994; 35(Suppl 35): A76.
34. Fumagalli I, Hammer B. Cisapride versus metoclopramide in the treatment of functional dyspepsia: a double-blind comparative trial. Scand J Gastroenterol 1994; 29: 33-37.
35. Heyse PM, Rambaldo R, Hazelhoff B. Factors affecting short-and long-term outcome of a short therapeutic trial with cisapride in dyspeptic patients. Scand J Gastroenterol 1993; 28(Suppl 195): 15-24.
36. Talley NJ, Phillips SF, Bruce B et al. Multisystem complaints in patients with the irritable bowel syndrome and functional dyspepsia. Eur J Gastroenterol Hepatol 1991; 3: 71-77.
37. Talley NJ, Colin-Jones D, Koch KL et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterology Int 1991; 4: 145-160.
38. Liehr H, Schmidt R. A German drug-monitoring study in general practice patients receiving cisapride for functional dyspepsia. Scand J Gastroenterol 1993: 28(Suppl 195): 54-58.
39. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-69.
40. Saunders JHB, Oliver RJ, Higson DL. Dyspepsia: incidence ot non-ulcer disease in a controlled trial of ranitidine in general practice. BMJ 1986; 292: 665-668.
41. Johannessen T, Fjosne U, Kleveland P et al. Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol 1988; 23: 327-336.
42. Archimandritis A, Tzivras M, Emmanuel A et al. Cisapride, metoclopramide and ranitidine in the treatment of severe non-ulcer dyspepsia. Clin Ther 1992; 14:553-561.
43. Nyren O. Therapeutic trial in dyspepsia: its role in the primary care setting. Scand J Gastroenterol 1991; 26(Suppl 182): 61-69.
44. Jebbink HJA, Smout AJPM, Van Berge-Henegouwen GP. Pathophysiology and treatment of functional dyspepsia. Scand J Gastroenterol 1993; 28(Suppl 200): 8-14.
45. Holtmann G, Neufang-Hober J, Talley NJ, Goebell H. Pattern of symptoms in functional dyspepsia: predictors of a response to treatment? DDW 1996; 1548 (Abstract).
46. Vaz Safatle Ribeiro A, Reynolds JC. Cisapride: mechanisms of action and potential applications. Today's Ther Trends 1994; 12: 1-23.
47. Kellow JE, Cowan H, Shuter B et al. Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995; 9: 153-160.
48. Inauen W, Emde C, Weber B et al. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24-hour ambulatory combined pH and manometry study. Gut 1993; 34: 1025-1031.
49. Dent J, Watts R, Riley S et al. Gastroesophageal reflux disease in primary care - an international placebo-controlled study of different treatment strategies with omeprazole. DDW 1996; 3952 (Abstract).
50. Carlsson R, Dent J, Glise H et al. Evaluation of a questionnaire for the diagnosis of symptomatic gastroesophageal reflux disease. DDW 1996B: 3956 (Abstract).